KHIDI Brief - US Regulatory Landscape for Therapeutic Products
- KHIDI USA
- Nov 4, 2021
- 1 min read
Table of Contents
Entering the US Market for pharmaceutical and medical device products
- FDA Regulation on Therapeutic Products
- Regulatory challenges in entering the US market
- Preparation for regulatory support
2. COVID-19 and FDA policies during the pandemic
- Emergency Use Authorization - Overview
- EUA for medical devices and pharmaceuticals
- Changes in the FDA due to the pandemic
3. Supply chain for therapeutic products in the US
- Shortcomings in the US supply chain for therapeutic products revealed by COVID19
- Biden Administration's "America's Supply Chains" executive order and its impact in the healthcare/ biopharma industry
4. Summary and Implications
![[KHIDI Webinar] Get Ready for J.P. Morgan 2026!! (1.8.2026)](https://static.wixstatic.com/media/a5656b_58f6cacb87a640acad491a2592d7a207~mv2.png/v1/fill/w_980,h_551,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/a5656b_58f6cacb87a640acad491a2592d7a207~mv2.png)
Comments